Intriguing and thought provoking talk by Madhuri Koti on aging and sex differences of immune response to BCG in #bladdercancer #IBCN23 IBCN

Fantastic talk by Dr. Byron Lee MD Anderson Cancer Center on KDM6A alterations in #bladdercancer at #IBCN23 IBCN 🌟🙌🏻

Elena Aramendia from our group presented her work on optimizing a RF Lund taxonomy classifier. Great presentation! #IBCN23

Very proud of Kartiksachdeva and Priyanka Yolmo from QCRI Queen's QUbiomed , for sharing their exciting findings on sex differences in immunity to #bladdercancer at #IBCN23 IBCN

Thank you Lars Dyrskjøt and Kent Mouw for inviting to speak at the IBCN23 meeting! A session on aging and sex differences in immunity #bladdercancer was such a great idea!!

And…thank you, Priyanka Priyanka Yolmo, for sharing this pic! 😀

Superb talks by the rising stars in #bladdercancer Trine Strandgaard Gillian Vandekerkhove Eva Michaud Jethro Kwong Jeop de Jong at #IBCN23 IBCN

#ibcn23 day 2… starting with Aging Sex and Impact on immunity and treatment response in #bladdercancer .. full room Madhuri Koti Sean Li .. exciting research on mechanism behind the development and tx disparities

The countdown for #IBCN23 has begun - looking forward to see many friends and colleagues in Montreal Thursday evening for another great meeting. Wes Kassouf Kent Mouw Peter Black Tilman Todenhöfer Roland Seiler-Blarer IBCN Stephen B. Williams, MD, MBA, MS, FACHE

And of course my favorite person in the world Phillip Abbosh rounding off #ibcn23 experience with uDNA in bladder cancer as marker of residual disease Fox Chase Cancer Center Au revoir Montreal 🇨🇦 it’s been fab

First time attending a IBCN meeting and really enjoyed the first day of #IBCN23 ! Beautiful keynote talk from Michael Shen and great presentation from our student Michele Garioni on #bladdercancer patient-derived #organoids .

Was a terrific meeting! Now updated on all the great science advancing #bladdecancer research by great colleagues at #IBCN23 ! Wes Kassouf, Sean Li, Lars Dyrskjøt, Ekta Kapadia, Hema Dave, Sita Vermeulen Peter Black Ashish M. Kamat, MD, MBBS Kent Mouw Gottfrid Sjödahl David M. Berman and many more!

Exploratory data from the -ve KN361 trial of chemo/pembro vs chemo in bladder cancer #IBCN23 . Cis/pembro looks a bit better than carbo/pembro for PFS & RR but not OS(68% got 2nd line therapy). Unclear how much maintenance pembro helped. 1st line Cis/nivo has +ve OS-CM901 @esmo23

Always a delight to reunite with Shivi Cumarasamy and Phillip Abbosh from FoxChaseCancer at #ibcn23 💌

#IBCN23 is off to great start with key note speaker Michael Shen discussing organoids in translational research , KMT2D and plasticity

interest in HER 2 & 3 expression in urothelial cancer due to new ADCs. Exploratory analysis from R3 LAMB trial shows ~50% of tumors are HER2 and HER3 +ve. HER2 maybe associated with short PFS. Disitimab vedotin in R3 in 1st line UC, HER3 ADCs awaited in UC Bernadett Szabados @IBCN23

Great talk by Kent Mouw presenting ERCC2 and ATM mutations and cisplatin sensitivity testing through functional analysis .. super informative #ibcn23

#IBCN23 Dr. Michele Garioni presented organoids, treatments, and sarcomatoid bladder cancer.

#IBCN23 keynote speaker Dr. Seth Lerner presenting past, present, and future of TCGA and bladder cancer.

Looking forward to #IBCN23 and great line up of speakers and of course get a chance to see my fav Phillip Abbosh . Special 🙏 to Lars Dyrskjøt Kent Mouw for the invitation to discuss sex dependent variation in immune response/🧫oncobiome in #bladdercancer

#IBCN23 Dr. Jeffrey Damrauer presented meta analysis of GWAS from diverse populations in bladder cancer.